Rundu Shares announced that the company recently received two Drug Registration Certificates for Azilsartan Medoxomil Potassium Tablets issued by the National Medical Products Administration. The drug is indicated for the treatment of essential hypertension in adults. This approval further improves the company's product layout in the cardiovascular and cerebrovascular treatment field, promotes the formation of a vertically integrated industrial chain from active pharmaceutical ingredients to finished formulations, and helps enhance market competitiveness.
Zhuhai Rundu Pharmaceutical Co Ltd Class AReceived drug registration certificates for Azilsartan Medoxomil Potassium Tablets from NMPA, expanding product portfolio in cardiovascular field.